Bank of America downgrades Bluebird bio's stock to "Neutral," reflecting the biotech's financial struggles. Bank of America degrada el stock de Bluebird a "Neutral", reflejando las luchas financieras de la biotecnología.

Bank of America downgraded Bluebird bio's stock from "Buy" to "Neutral," lowering the target price to $0.50. Bank of America redujo las acciones de Bluebird de "Comprar" a "Neutral", bajando el precio objetivo a $0.50. The biotech company, which develops gene therapies for severe genetic diseases, has seen mixed ratings from analysts. La compañía biotecnológica, que desarrolla terapias génicas para enfermedades genéticas graves, ha visto calificaciones mixtas de analistas. Despite recent downgrades, some like Barclays still rate it "Overweight." A pesar de las recientes rebajas, algunos como Barclays todavía lo califican de "sobrepeso". Bluebird bio's stock fell to $0.32, reflecting negative financial metrics like a 567.29% negative net margin. El stock de Bluebird bio cayó a $0,32, reflejando métricas financieras negativas como un margen neto negativo de 567,29%. Institutional investors have increased their stakes in the company. Los inversores institucionales han incrementado sus participaciones en la empresa.